Dermtech has filed for Chapter 11 bankruptcy protection and laid off 20% of its staff to support its push to find a buyer for its cancer test technology, the company said Tuesday. The San Diego-based ...
SAN DIEGO, March 26, 2026 /PRNewswire/ -- DermTech 2.0 ("DermTech LLC" or "The Company"), a leader in precision dermatology enabled by DermTech's proprietary non-invasive Smart Sticker ® skin sample ...
DermTech (NASDAQ: DMTK) is trying to redefine the process for identifying skin cancer. The current approach involves a visual inspection and an invasive biopsy -- a highly inaccurate method that most ...
NEW YORK & LA JOLLA, Calif.–(BUSINESS WIRE)–Constellation Alpha Capital Corp. (“Constellation”, NASDAQ: CNAC), a publicly-traded special purpose acquisition ...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the ...
DermTech (NASDAQ: DMTK) and GoodRx (NASDAQ: GDRX) have been huge losers for investors over the last 12 months. In this Motley Fool Live video, recorded on Jan. 12., Fool contributors Keith Speights ...
DermTech, a San Diego biotechnology company that developed a noninvasive melanoma test, is reducing its workforce by 15 percent to shave off operating expenses. The company announced last week that it ...
DermTech's new product could revolutionize how doctors test for skin cancer. 10x Genomics is turbocharging research in cells and genes. Both companies offer disruptive new solutions in their niches of ...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results